Orforglipron: A Needle-Free GLP-1 Option for Weight Management | Dr. Dan | Obesity Expert [keto gummies amazon]

Orforglipron: A Needle-Free GLP-1 Option for Weight Management | Dr. Dan | Obesity Expert [keto gummies amazon]

| 1h 28m 28s | Video has closed captioning.

Is Orforglipron the Obesity Weight Loss Breakthrough We've Been Waiting For? Is it better than Rybelsus and Oral Wegovy? If you need assistance in your journey to reach your weight loss goals, book a consultation with me: Join this channel to get access to perks: Download my FREE GLP-1/GIP Medication Information Sheet: Try my fancy dancy Total Daily Energy Expenditure (TDEE) Calculator: Subscribe to the channel: – I have great news for those who dislike needles or prefer a daily reminder to engage in positive behaviors. There’s a new oral GLP-1 molecule making its way to market called Orforglipron! Currently, Rybelsus is the only oral GLP-1 available, approved for diabetes management up to a dose of 14mg once daily. Rybelsus contains semaglutide, found in Ozempic and Wegovy, but it’s not yet approved for weight management. Orforglipron, on the other hand, is a game-changer. It’s an oral nonpeptide GLP-1 receptor agonist that can be taken without regard to food, drink or other medications. It’s designed to be absorbed through the digestive tract, without needing an absorption enhancer like Rybelsus. This makes it more convenient for daily use. So, how effective is Orforglipron? The Phase 2 RCT trial involved 272 participants with obesity, split into groups receiving either 12mg, 24mg, 36mg, or 48mg of Orforglipron daily, or a placebo. Participants received basic counseling on healthy eating and exercise. The study found that participants, mostly female with an average age of 54, weight of 108.7kg, and BMI of 37.9, saw impressive results. Those on 45mg daily of Orforglipron lost 14.7% of their baseline weight after 36 weeks, and the weight loss trend hadn’t plateaued yet. For reference, this is comparable to results from the OASIS Trial with oral semaglutide at 50mg daily, which led to a 15.1% weight loss after 68 weeks. Safety-wise, the side effects were typical for GLP-1 receptor agonists: nausea, vomiting, diarrhea, and constipation. Nothing out of the ordinary here. Orforglipron is a promising new oral GLP-1 RA that might offer a more convenient and potentially more effective option for weight management. Its smaller molecule size might also mean a cheaper alternative, though time will tell. Thanks for watching and always remember: small tweaks lead to massive peaks! - Dr. Dan – Products I recommend to support your weight-loss journey: ▪️ Managing Constipation: ▪️ Managing Diarrhea: ▪️ Managing Heartburn: ▪️ Internalized Weight Bias: ▪️ Protein Bars: ▪️ Scales and More: ▪️ Supplements: ▪️ Activity Trackers I recommend: ▪️ My favorite Books: 🇺🇸 USA: 🇨🇦 Canada: Watch my previous videos about how to fight obesity and about the best medicine for weight loss: ▪️ Rybelsus: Oral Ozempic?: ▪️ Watch This Before Taking Mounjaro: ▪️ From Ozempic to Mounjaro: ▪️ Muscle Loss with Ozempic, Wegovy & Mounjaro: ▪️ Managing Nausea from Ozempic, Wegovy and Trulicity!: ▪️ Ozempic: Stomach Paralysis Update: ▪️ Ozempic Paralyzed My Stomach: – Live in Alberta? Come see me at my Pharmacist-led Obesity Clinic at Apothecare Pharmacy - – Sign up for my newsletter: – Contact Me: [email protected] – Have questions or need support on your weight-loss journey? Book a consultation with me: – For more about weight loss via habit mastery, visit Join me on social media: ▪️ ▪️ ▪️ Disclaimer of Medical Liability. HEALTHCARE EVOLUTION INC. DOES NOT PROVIDE MEDICAL ADVICE. The content of this material is for general informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Reliance on any information provided here is solely at your own risk. Individual medical needs are very different; you should not assume that the information in this document concerning certain courses of treatment or outcomes will apply to you. Rather, you should evaluate your medical condition and make treatment decisions based upon consultation with your physician. #Obesity #Orforglipron #Wegovy